Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675452 · ClinicalTrials.gov registry record · Phase 1
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT02675452 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 141 participants.
The verdict
NCT02675452, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
Interventions
- DRUG Azacitidine
- DRUG Itraconazole
- DRUG AMG 176
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2024-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675452
The ClinicalTrials.gov registry entry for NCT02675452 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT02675452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675452 about?
NCT02675452 is a clinical study titled "AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia". The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
What is the current status of trial NCT02675452?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2016-06-13. Estimated completion is 2024-05-27.
What interventions are being tested in trial NCT02675452?
The interventions under investigation include: Azacitidine (DRUG), Itraconazole (DRUG), AMG 176 (DRUG).
Who is sponsoring clinical trial NCT02675452?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.